Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib safety, tolerability, efficacy, and pharmacokinetics study in relapsed or refractory acute leukemias
NL-OMON59985Phase 2Active, not recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of revumenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL) and 1 more (10 arms), sponsored by Syndax Pharmaceuticals. Started May 2022; status: active, not recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)Acute Leukaemia
Beyond the preview
Go deeper on NL-OMON59985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59985.